Login / Signup

Successful treatment of adult-onset nesidioblastosis by continuous subcutaneous octreotide infusion in a patient on hemodialysis.

Rina KatoAkihiro NishimuraKimio MatsumuraShota KikunoKaoru NagasawaYasumichi Mori
Published in: Clinical case reports (2020)
Octreotide may be useful in noninsulinoma pancreatogenous hypoglycemia syndrome with nesidioblastosis patients who was on hemodialysis. Continuous octreotide subcutaneous infusion can reduce side-effects and stabilize plasma glucose levels.
Keyphrases
  • neuroendocrine tumors
  • end stage renal disease
  • peritoneal dialysis
  • case report
  • chronic kidney disease
  • low dose
  • type diabetes
  • blood glucose
  • blood pressure